For a product manager in the dietary supplement industry, launching a new item is less about a eureka moment and more about a compliance marathon. The process involves sifting through a sprawling, fragmented body of scientific literature to substantiate claims, identify safe and effective ingredients, and match with verified suppliers, all under the watchful eye of regulators. IngredientAI, a New York-based startup founded in 2023, is betting that an AI trained on tens of millions of studies can turn that slog into a searchable, compliant workflow [CRN USA, pre-2026].
The wedge of compliant research
IngredientAI’s core proposition is discovery within guardrails. The platform is designed to surface insights from clinical trials, pharmacological databases, and regulatory filings, aiming to accelerate formulation research and ingredient discovery for brands and their suppliers [The Org, 2026]. The output includes AI-powered supplier matching and automated dossier generation to help substantiate claims and speed products to market [Tola Capital, 2026]. For CEO Akash Shah, a co-founder of the now-shuttered vitamin subscription service Care/of, the problem is familiar. His previous venture navigated the consumer side of this complex supply chain, raising $15 million before its closure in 2024 [TechCrunch, 2024] [Forbes, 2018].
A founder with scar tissue
Shah’s background is the company’s most tangible asset. Building and ultimately winding down Care/of provided a ground-level view of the innovation and compliance challenges facing supplement brands. While the startup has not disclosed funding rounds or amounts, its investor roster includes established firms like Maverick Ventures and Tola Capital [Tola Capital, 2026]. The early team also includes Jonathan O. as Head of Product & Sales Operations, a role he has held since September 2024 [The Org, 2026].
| Role | Name | Key Background |
|---|---|---|
| Co-Founder & CEO | Akash Shah | Co-founded Care/of (2016-2024). Forbes 30 Under 30 alum [Forbes, 2018]. |
| Head of Product & Sales Operations | Jonathan O. | Joined IngredientAI in September 2024 [The Org, 2026]. |
Navigating a landscape of limited signals
The company’s current profile presents a classic early-stage puzzle. Public traction signals, named customers, and detailed case studies are absent from the record. The product claims are not yet backed by third-party validation. In a sector where regulatory compliance is non-negotiable, the platform’s ability to reliably navigate the nuanced boundaries of structure/function claims versus disease claims will be its ultimate test. Furthermore, the competitive field includes companies like Brightseed, which uses AI to discover novel bioactive compounds in plants, suggesting a crowded and well-funded arena.
The risks for IngredientAI center on validation and adoption:
- Regulatory rigor. The platform’s output must meet the evidentiary standards of the FDA’s Office of Dietary Supplement Programs and the Federal Trade Commission.
- Commercial proof. The leap from a powerful research tool to a must-have SaaS platform requires demonstrating a clear return on investment.
- Data differentiation. The value hinges on a proprietary dataset or a uniquely effective synthesis of public data.
What the standard of care looks like today
For context, the current process for developing a new dietary supplement is notoriously manual. A brand’s research team typically conducts exhaustive literature reviews across disconnected databases like PubMed, embarks on lengthy supplier audits, and engages legal counsel to painstakingly build regulatory dossiers. This standard of care is slow, expensive, and inconsistent, creating a high barrier to innovation. It is this friction that IngredientAI is attempting to automate.
The next twelve months will be critical for the startup to transition from a promising concept to a commercial entity. Key milestones will include announcing its first publicly referenced customer deployments, detailing the specific architecture of its AI and data sources, and potentially disclosing its first formal funding round.